Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sodium chloride, quantity: 900 mg - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - for the restoration and maintenance of salt and extracellular fluid levels or as a vehicle for the administration of parenteral drugs.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sodium chloride, quantity: 450 mg - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - for the restoration and maintenance of salt and extracellular fluid levels or as a vehicle for the administration of parenteral drugs.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 16.7mg equivalent to sunitinib 12.5mg;   - capsule - 12.5 mg - active: sunitinib malate 16.7mg equivalent to sunitinib 12.5mg   excipient: croscarmellose sodium gelatin ink iron oxide red magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - treatment of advanced renal cell carcinoma

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 33.4mg equivalent to sunitinib 25mg;   - capsule - 25 mg - active: sunitinib malate 33.4mg equivalent to sunitinib 25mg   excipient: croscarmellose sodium gelatin ink iron oxide black iron oxide red iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - treatment of advanced renal cell carcinoma

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 50.1mg equivalent to sunitinib 37.5mg;   - capsule - 37.5 mg - active: sunitinib malate 50.1mg equivalent to sunitinib 37.5mg   excipient: croscarmellose sodium gelatin ink iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - treatment of advanced renal cell carcinoma

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 66.8mg equivalent to sunitinib 50mg;   - capsule - 50 mg - active: sunitinib malate 66.8mg equivalent to sunitinib 50mg   excipient: croscarmellose sodium gelatin ink iron oxide black iron oxide red iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - treatment of advanced renal cell carcinoma

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - exemestane -

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - exemestane -

United States - English - NLM (National Library of Medicine)

pfizer manufacturing belgium nv - tozinameran (unii: 5085zfp6sj) (tozinameran - unii:5085zfp6sj), bnt162b2 omicron (ba.4/ba.5) (unii: jsv288q5cv) (bnt162b2 omicron (ba.4/ba.5) - unii:jsv288q5cv) -

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pfizer saudi limited, saudi arabia - bnt162b2 - suspension for injection - 30 µg